Bradyrhizobiaceae

Most bacteria on a gut panel are gut residents. This one usually isn't. Bradyrhizobiaceae is a family of soil and water bacteria whose best-known members live around plant roots and help plants use nitrogen from the air.

So when its DNA shows up in your stool, the first question isn't how high it is. It's what this is doing here at all. For nearly everyone, it is probably passing through from food, water, or soil exposure.

What the Test Actually Detects

PCR is a DNA-copying method. Here it is used to look for bacterial DNA in stool.

Many panels report this at the family level. That matters: a family-level stool result cannot tell you whether the DNA came from Bradyrhizobium enterica or from another related environmental bacterium unless the lab reports the organism more specifically.

Detecting DNA tells you genetic material was present in the sample. It does not prove live bacteria are colonizing your intestine, and it does not prove infection.

Most familiar Bradyrhizobiaceae are plant-associated. The human-associated organism described in cord colitis behaves differently: its draft genome appears to lack several genes needed for nitrogen fixation.

Cord Colitis Syndrome

The closest human disease evidence is narrower than a stool result. In 2013, researchers sequenced colon tissue from people who developed a puzzling form of colitis after umbilical cord blood stem cell transplants and found DNA from a previously unknown bacterium, provisionally named Bradyrhizobium enterica.

The organism appeared in the cord colitis tissue samples they tested and was absent from comparison samples from healthy people, colon cancer patients, and transplant recipients with graft-versus-host disease. Its signal rose around the time colitis began and fell after antimicrobial treatment, though that signal was a rough band-intensity read rather than a precise quantity.

That is suggestive. It is not proof. This was a handful of patients at a single hospital: the draft genome was assembled from sequenced biopsy tissue, and the organism was then confirmed by targeted testing in three more cord colitis patients. Its genome carries genes for proteins that help some bacteria stick to body linings, but nobody has shown that this organism causes colitis in people.

That is also a related but different measurement: species-level DNA in colon tissue from highly immunocompromised transplant recipients, not a family-level signal in stool.

The population this finding applies to is narrow. If you have not had an umbilical cord blood transplant and are not severely immunocompromised, this research tells you almost nothing about your own result.

Why a Detection Usually Isn't an Alarm

One study found a related organism in all tested cord colitis cases, and that sounds like a strong disease link. Yet a detection on your stool panel usually means very little.

Those are two different questions. Do people with this rare colitis have the organism? Do people with the organism have colitis? Outside severely immunocompromised transplant recipients, no study has tied a stool Bradyrhizobiaceae result to disease, symptoms, or outcomes.

There is one other thread, and it is thin. A study of the salivary microbiome in an urban Indian cohort found unclassified Bradyrhizobiaceae was more common in people whose interleukin-1 beta sat in the top quarter of the group. Interleukin-1 beta is an inflammation signal. That was 51 people, a different specimen, and an exploratory correlation with a lab marker rather than a disease. Treat it as a hypothesis, not as a finding about your gut.

There Are No Reference Ranges

This changes how you should read your report. No validated reference range exists for Bradyrhizobiaceae in stool. There is no consensus threshold separating normal from abnormal, no cutoff tested against clinical outcomes, and no professional guideline recommending the test for any indication.

Numbers from different labs also aren't directly comparable. Microbiome profiling varies a lot between studies depending on how samples are collected and which genetic targets the assay copies. A result that looks high on one platform may not mean the same thing on another.

This is a research-oriented measurement on microbiome panels. It is not a diagnostic test, and an isolated value should not drive treatment.

What the Rest of Your Panel Is Telling You

If a stool panel can help, the useful signal will usually come from resident bacteria, inflammation markers, and established pathogens, not this line.

Butyrate is a small fat that gut bacteria make from fiber and that colon cells use for fuel. In Parkinson's disease, for example, the most reproducible pattern across studies is lower abundance of fiber-fermenting groups such as Lachnospiraceae and Faecalibacterium, with Prevotellaceae lower in most studies though results there vary. Those are resident patterns. A soil bacterium arriving with food is a different kind of event.

So when you read your report, weight the core resident organisms heavily and treat environmental detections as background unless something in your clinical picture says otherwise.

Why a Single Reading Can Fool You

Low-abundance organisms swing hard. In a study where 20 healthy women gave daily stool samples for six weeks, 72% of the more abundant bacterial genera showed more than 10-fold changes between consecutive samples, and 40% of them showed 100-fold changes over the study period. Stool moisture explained more of that variation than diet did.

A nonresident environmental signal will be even jumpier than that. A single detection may reflect what you ate three days ago more than anything about your gut.

Two other things distort readings. Recent antibiotics reshape the whole community: richness typically recovers within about two months in healthy adults, but taxonomic composition can stay altered longer, and a large prescription-linked study found the strongest associations in the first year with some lasting four to eight years. PCR can also copy DNA from dead bacteria, so a detection can represent dead organisms from food or water passing through.

Tracking Your Trend

Given the variability, one reading tells you almost nothing about this particular organism. There is no medical need to trend it by itself.

If you repeat the broader gut panel anyway, use the same lab and similar collection conditions. What you are looking for is whether the signal persists across samples or disappears. Persistence is more meaningful than a single positive, but it still has no validated clinical cutoff.

Serial testing can give context for the whole panel. It cannot tell you whether a diet, probiotic, prebiotic, or antibiotic worked on this family, because human intervention data have not established a Bradyrhizobiaceae-specific effect.

What to Do With an Unexpected Result

Start by reading the whole panel rather than the one line that caught your eye. If your fiber-fermenting families look intact, your diversity metrics are reasonable, and no pathogen showed up, a Bradyrhizobiaceae detection alongside them is not a finding that needs action.

If you have real gastrointestinal symptoms, the workup that helps is a different one. A validated stool PCR panel targeting established enteric pathogens, such as Campylobacter, Salmonella, Shigella, C. difficile, and common enteric viruses, answers a more concrete question. Common targets on FilmArray-type panels usually show sensitivity above 90% and specificity near or above 98%, depending on the organism, and results can come back in hours.

Fecal calprotectin is a stool marker released by white blood cells in an inflamed gut lining. It is far more useful for sorting inflammatory bowel disease from irritable bowel syndrome than an environmental organism is: pooled across adult studies, it picks up about 86% of inflammatory bowel disease cases and correctly clears about 92% of people without it. Those two tests together answer more than this family-level signal can.

Involve a gastroenterologist when symptoms are persistent, when there is blood in the stool, or when a pathogen panel and calprotectin do not fit how you feel. Bring the whole picture, not the single taxon. Repeat pathogen panel testing within two weeks rarely adds actionable information, so resist the urge to re-order immediately.

The one scenario that changes this calculus is severe immunosuppression, particularly after a cord blood stem cell transplant. If that describes you and you are having colitis symptoms, this detection is worth raising with your transplant team directly, because that is the only population where a related organism has been linked to disease.